Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating
Palisade Bio, Inc. (NASDAQ:PALI) Receives $13.25 Average Price Target from Analysts
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Palisade Bio: Gut Prodrug For IBD With Catalysts
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher
All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases